TKPHF
Takeda Pharmaceutical Company Limited
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Sell
-26/100
Last price
33.85
▼ 1.90 (5.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
35.75
Day high
35.75
Day low
35.75
Volume
200
Market cap
$54.07B
P/E (TTM)
—
52W range
26.33 – 39.20
Trailing performance
Returnvs SPY
1W
-8.51%
-10.5%
1M
-8.02%
-9.2%
3M
-2.45%
-7.0%
6M
-1.94%
-20.1%
YTD
+9.80%
-4.5%
1Y
+16.72%
+0.3%
3Y
+9.48%
-72.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TKPHF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
537.30K
Total on file
Fundamentals
Market cap$54.07B
Enterprise value$5.13T
Revenue (TTM)$4.62T
Gross profit$2.98T
EBITDA$1.25T
Net income$-163.44B
EPS (TTM)$-0.68
Free cash flow$541.44B
Total cash$460.98B
Total debt$5.54T
Book value / share$30.30
Shares outstanding1.60B
Float1.58B
Short % of float—
Dividend yield3.81%
Beta (5Y)0.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E41.79
PEG ratio0.38
Price / sales—
Price / book1.12
EV / revenue1.11
EV / EBITDA4.11
Gross margin64.47%
Operating margin16.45%
Profit margin-3.54%
Return on equity-2.26%
Return on assets2.69%
Debt / equity73.25
Current ratio1.14
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.51T | $4.58T | $4.26T | $4.03T | -1.7% |
| Operating revenue | $4.51T | $4.58T | $4.26T | $4.03T | -1.7% |
| Cost of revenue | $1.57T | $1.58T | $1.43T | $1.24T | -0.5% |
| Gross profit | $2.93T | $3.00T | $2.84T | $2.78T | -2.2% |
| Research & development | $675.92B | $730.23B | $729.92B | $633.33B | -7.4% |
| Selling, general & admin | $1.08T | $1.10T | $1.05T | $997.31B | -1.9% |
| Total operating expense | $2.47T | $2.53T | $2.53T | $2.20T | -2.6% |
| Operating income | $464.45B | $466.37B | $309.90B | $587.81B | -0.4% |
| Net interest income | -$143.77B | -$160.55B | -$140.46B | -$123.39B | +10.5% |
| Pre-tax income | -$142.35B | $175.08B | $52.79B | $375.09B | -181.3% |
| Tax provision | $9.77B | $66.94B | -$91.41B | $58.05B | -85.4% |
| Net income | -$152.39B | $107.93B | $144.07B | $317.02B | -241.2% |
| Net income to common | -$152.39B | $107.93B | $144.07B | $317.02B | -241.2% |
| Basic EPS | 121.75 | 68.36 | 92.09 | 204.29 | +78.1% |
| Diluted EPS | 119.64 | 67.23 | 91.16 | 201.94 | +78.0% |
| EBIT | $5.77B | $312.39B | $172.33B | $492.06B | -98.2% |
| EBITDA | $726.89B | $1.07T | $900.33B | $1.16T | -32.3% |
| Basic shares | 1.58B | 1.58B | 1.56B | 1.55B | -0.2% |
| Diluted shares | 1.60B | 1.61B | 1.58B | 1.57B | -0.2% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $595.05B | $385.11B | $457.80B | $533.53B | +54.5% |
| Cash & short-term investments | $636.94B | $405.59B | $472.89B | $553.70B | +57.0% |
| Accounts receivable | $977.36B | $770.90B | $718.67B | $674.69B | +26.8% |
| Inventory | $1.40T | $1.22T | $1.21T | $986.46B | +14.7% |
| Total current assets | $3.09T | $2.52T | $2.56T | $2.40T | +22.6% |
| Property, plant & equipment | $2.12T | $1.97T | $1.99T | $1.69T | +7.7% |
| Goodwill & intangibles | $9.23T | $8.96T | $9.68T | $9.06T | +3.0% |
| Total assets | $15.51T | $14.25T | $15.11T | $13.96T | +8.9% |
| Total current liabilities | $2.83T | $2.51T | $2.31T | $2.48T | +13.0% |
| Current debt | $512.16B | $548.94B | $367.25B | $339.60B | -6.7% |
| Long-term debt | $4.37T | $3.97T | $4.48T | $4.04T | +10.2% |
| Total debt | $4.88T | $4.52T | $4.84T | $4.38T | +8.1% |
| Total liabilities | $8.08T | $7.31T | $7.83T | $7.60T | +10.5% |
| Retained earnings | $712.38B | $1.19T | $1.39T | $1.54T | -40.0% |
| Shareholder equity | $7.43T | $6.94T | $7.27T | $6.35T | +7.1% |
| Working capital | $258.43B | $14.67B | $245.48B | -$83.98B | +1,661.5% |
| Net tangible assets | -$1.80T | -$2.02T | -$2.41T | -$2.71T | +11.0% |
| Shares issued | 1.59B | 1.59B | 1.58B | 1.58B | +0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$152.13B | $108.14B | $144.20B | $317.04B | -240.7% |
| Depreciation & amortisation | $721.13B | $761.40B | $728.00B | $664.40B | -5.3% |
| Stock-based compensation | $72.78B | $72.87B | $70.87B | $60.67B | -0.1% |
| Change in working capital | $199.91B | -$59.37B | -$256.00B | -$25.26B | +436.7% |
| Operating cash flow | $1.04T | $1.06T | $716.34B | $977.16B | -1.5% |
| Capital expenditure | -$414.66B | -$379.63B | -$480.73B | -$633.69B | -9.2% |
| Investing cash flow | -$369.14B | -$367.06B | -$463.86B | -$607.10B | -0.6% |
| Share buybacks | -$51.60B | -$51.86B | -$2.33B | -$26.93B | +0.5% |
| Dividends paid | -$311.90B | -$302.50B | -$287.19B | -$279.42B | -3.1% |
| Financing cash flow | -$496.82B | -$751.42B | -$354.42B | -$709.15B | +33.9% |
| Free cash flow | $626.77B | $677.56B | $235.61B | $343.47B | -7.5% |
| End cash position | $595.05B | $385.11B | $457.80B | $533.53B | +54.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.22T | $1.09T | $1.19T | $1.11T | $1.11T | +11.5% |
| Operating revenue | $1.22T | $1.09T | $1.19T | $1.11T | $1.11T | +11.5% |
| Cost of revenue | $406.68B | $405.70B | $401.15B | $380.06B | $384.68B | +0.2% |
| Gross profit | $813.22B | $688.84B | $790.55B | $732.74B | $722.01B | +18.1% |
| Research & development | $167.40B | $195.32B | $175.23B | $161.48B | $143.89B | -14.3% |
| Selling, general & admin | $286.51B | $292.00B | $282.78B | $253.55B | $255.88B | -1.9% |
| Total operating expense | $611.81B | $646.77B | $621.73B | $663.74B | $537.45B | -5.4% |
| Operating income | $201.42B | $42.07B | $168.82B | $69.00B | $184.56B | +378.8% |
| Net interest income | -$39.24B | -$35.88B | -$35.76B | -$38.74B | -$33.40B | -9.4% |
| Pre-tax income | $162.72B | -$455.02B | $133.86B | $28.17B | $150.63B | +135.8% |
| Tax provision | $49.46B | -$86.61B | $30.13B | $39.90B | $26.35B | +157.1% |
| Net income | $113.20B | -$368.47B | $103.64B | -$11.80B | $124.24B | +130.7% |
| Net income to common | $113.20B | -$368.47B | $103.64B | -$11.80B | $124.24B | +130.7% |
| Basic EPS | 71.65 | — | — | — | 79.40 | — |
| Diluted EPS | 70.54 | — | — | — | 78.23 | — |
| EBIT | $226.56B | -$620.82B | $257.49B | $111.31B | $257.79B | +136.5% |
| EBITDA | $337.49B | -$456.95B | $448.13B | $316.47B | $389.43B | +173.9% |
| Basic shares | 1.58B | — | — | — | 1.56B | — |
| Diluted shares | 1.60B | — | — | — | 1.59B | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $460.98B | $595.05B | $654.94B | $681.49B | $350.01B | -22.5% |
| Cash & short-term investments | $527.58B | $636.94B | $761.94B | $739.68B | $419.18B | -17.2% |
| Accounts receivable | $930.38B | $977.36B | $736.46B | $688.96B | $665.63B | -4.8% |
| Inventory | $1.45T | $1.40T | $1.41T | $1.30T | $1.24T | +3.6% |
| Total current assets | $3.15T | $3.09T | $3.12T | $2.92T | $2.51T | +1.9% |
| Property, plant & equipment | $2.14T | $2.12T | $2.08T | $1.98T | $1.96T | +1.0% |
| Goodwill & intangibles | $9.28T | $9.23T | $9.27T | $8.73T | $8.72T | +0.5% |
| Total assets | $15.66T | $15.51T | $15.41T | $14.47T | $14.00T | +1.0% |
| Total current liabilities | $2.76T | $2.83T | $2.61T | $2.14T | $2.17T | -2.4% |
| Current debt | $519.97B | $512.16B | $583.15B | $293.86B | $371.14B | +1.5% |
| Long-term debt | $4.42T | $4.37T | $4.27T | $4.35T | $4.13T | +1.2% |
| Total debt | $4.94T | $4.88T | $4.85T | $4.65T | $4.51T | +1.2% |
| Total liabilities | $8.10T | $8.08T | $7.76T | $7.34T | $7.14T | +0.3% |
| Retained earnings | $667.01B | $712.38B | $1.10T | $1.15T | $1.16T | -6.4% |
| Shareholder equity | $7.56T | $7.43T | $7.64T | $7.13T | $6.87T | +1.7% |
| Working capital | $385.72B | $258.43B | $506.26B | $780.97B | $343.54B | +49.3% |
| Net tangible assets | -$1.72T | -$1.80T | -$1.63T | -$1.60T | -$1.85T | +4.4% |
| Shares issued | 1.59B | 1.59B | 1.59B | 1.59B | 1.59B | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | — | -$368.41B | $103.73B | -$11.73B | $124.28B | -$103.10B | — |
| Depreciation & amortisation | — | $163.87B | $190.64B | $184.98B | $181.64B | $189.77B | — |
| Stock-based compensation | — | $19.71B | $17.80B | $18.73B | $16.53B | $17.63B | — |
| Change in working capital | — | $251.00B | -$39.33B | $21.94B | -$33.70B | $2.87B | — |
| Operating cash flow | $127.60M | $74.53B | $373.25B | $378.23B | $215.40M | — | -99.8% |
| Capital expenditure | — | -$64.39B | -$222.37B | -$52.83B | -$75.07B | -$92.72B | — |
| Investing cash flow | -$87.70M | -$58.02B | -$229.80B | -$48.13B | -$33.20M | — | +99.8% |
| Share buybacks | — | $0 | $0 | $0 | -$51.60B | -$49.98B | — |
| Dividends paid | — | -$8.79B | -$149.03B | -$8.79B | -$145.29B | -$9.74B | — |
| Financing cash flow | -$180.30M | -$77.49B | -$192.45B | -$11.98B | -$214.90M | — | +99.8% |
| Free cash flow | $127.60M | $10.13B | $150.88B | $325.40B | $215.40M | — | -98.7% |
| End cash position | $461.00M | $595.05B | $654.94B | $681.49B | $350.00M | — | -99.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $1.15T | +3.6% |
| Next quarter | — | — | $1.22T | +2.7% |
| Current year | — | — | $4.70T | +694.6% |
| Next year | — | — | $4.79T | +1.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.03%
Held by institutions50.00%
Institutions holding462
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
36.61
-7.55% from price
SMA 20
36.72
-7.82% from price
SMA 50
35.80
-5.45% from price
SMA 100
33.96
-0.34% from price
SMA 200
33.79
+0.17% from price
EMA 12
36.32
-6.80% from price
EMA 26
36.29
-6.71% from price
EMA 50
35.70
-5.18% from price
RSI (14)
32.6
Neutral
MACD (12,26,9)
0.03
Hist -0.37
ATR (14)
0.43
1.27% of price
Realised vol 30D
43.1%
Annualised
Bollinger upper
38.77
20, 2σ
Bollinger lower
34.67
20, 2σ
50 / 200 cross
Golden
35.80 vs 33.79
Trend bias
Above 200
+0.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.05
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
43.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-24.9%
Peak to trough
Max drawdown 5Y
-29.6%
Peak to trough
ATR 14
0.43
1.27% of price
Beta (reported)
0.10
5Y monthly, from filing
Dividends & splits
Forward rate$1.29 / yr
Forward yield3.81%
5-year avg yield4.47%
Payout ratio280.18%
Ex-dividend dateMar 31, 2027
Next pay dateJun 28, 2010
Last split—
Split date—
Headlines
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
PR Newswire · 1d ago
Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run
Simply Wall St. · 6d ago
Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
Business Wire · 6d ago
Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative
Simply Wall St. · 6d ago
Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
Simply Wall St. · 7d ago
Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading
MT Newswires · 7d ago
Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
MT Newswires · 7d ago
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Business Wire · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.